Department of Endocrine and Metabolic Diseases, Istituto di Ricovero e Cura a Caratttere Scientifico (IRCCS), Istituto Auxologico Italiano, Milan, Italy.
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Front Public Health. 2021 Dec 22;9:736665. doi: 10.3389/fpubh.2021.736665. eCollection 2021.
Several studies suggest an association between serum 25-hydroxyvitamin D (25OHD) and the outcomes of Severe Acute Respiratory Syndrome Corona-Virus-2 (SARS-CoV-2) infection, in particular Coronavirus Disease-2019 (COVID-19) related severity and mortality. The aim of the present meta-analysis was to investigate whether vitamin D status is associated with the COVID-19 severity, defined as ARDS requiring admission to intensive care unit (ICU) or mortality (primary endpoints) and with the susceptibility to SARS-CoV-2 and COVID-19-related hospitalization (secondary endpoints). A search in PubMed, ScienceDirect, Web of Science, Google Scholar, Scopus, and preprints repositories was performed until March 31th 2021 to identify all original observational studies reporting association measures, or enough data to calculate them, between Vitamin D status (insufficiency <75, deficiency <50, or severe deficiency <25 nmol/L) and risk of SARS-CoV-2 infection, COVID-19 hospitalization, ICU admission, or death during COVID-19 hospitalization. Fifty-four studies (49 as fully-printed and 5 as pre-print publications) were included for a total of 1,403,715 individuals. The association between vitamin D status and SARS-CoV2 infection, COVID-19 related hospitalization, COVID-19 related ICU admission, and COVID-19 related mortality was reported in 17, 9, 27, and 35 studies, respectively. Severe deficiency, deficiency and insufficiency of vitamin D were all associated with ICU admission (odds ratio [OR], 95% confidence intervals [95%CIs]: 2.63, 1.45-4.77; 2.16, 1.43-3.26; 2.83, 1.74-4.61, respectively), mortality (OR, 95%CIs: 2.60, 1.93-3.49; 1.84, 1.26-2.69; 4.15, 1.76-9.77, respectively), SARS-CoV-2 infection (OR, 95%CIs: 1.68, 1.32-2.13; 1.83, 1.43-2.33; 1.49, 1.16-1.91, respectively) and COVID-19 hospitalization (OR, 95%CIs 2.51, 1.63-3.85; 2.38, 1.56-3.63; 1.82, 1.43-2.33). Considering specific subgroups (i.e., Caucasian patients, high quality studies, and studies reporting adjusted association estimates) the results of primary endpoints did not change. Patients with low vitamin D levels present an increased risk of ARDS requiring admission to intensive care unit (ICU) or mortality due to SARS-CoV-2 infection and a higher susceptibility to SARS-CoV-2 infection and related hospitalization.
一些研究表明,血清 25-羟维生素 D(25OHD)与严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的结果之间存在关联,尤其是与 2019 年冠状病毒病(COVID-19)相关的严重程度和死亡率。本荟萃分析的目的是研究维生素 D 状态是否与 COVID-19 严重程度相关,定义为需要入住重症监护病房(ICU)或死亡的急性呼吸窘迫综合征(ARDS)(主要终点),以及与 SARS-CoV-2 和 COVID-19 相关住院相关的易感性(次要终点)。
截至 2021 年 3 月 31 日,我们在 PubMed、ScienceDirect、Web of Science、Google Scholar、Scopus 和预印本数据库中进行了检索,以确定所有报告维生素 D 状态(不足<75、不足<50 或严重不足<25 nmol/L)与 SARS-CoV-2 感染、COVID-19 住院、入住 ICU 或 COVID-19 住院期间死亡之间关联措施或足够数据以计算它们的原始观察性研究。
共有 54 项研究(49 项为全文印刷出版物,5 项为预印本出版物),共纳入 1403715 人。在 17、9、27 和 35 项研究中分别报告了维生素 D 状态与 SARS-CoV2 感染、COVID-19 相关住院、COVID-19 相关 ICU 入院和 COVID-19 相关死亡率之间的关联。严重缺乏、缺乏和不足的维生素 D 都与 ICU 入院(比值比[OR],95%置信区间[95%CI]:2.63,1.45-4.77;2.16,1.43-3.26;2.83,1.74-4.61,分别)、死亡率(OR,95%CI:2.60,1.93-3.49;1.84,1.26-2.69;4.15,1.76-9.77,分别)、SARS-CoV-2 感染(OR,95%CI:1.68,1.32-2.13;1.83,1.43-2.33;1.49,1.16-1.91,分别)和 COVID-19 住院(OR,95%CI 2.51,1.63-3.85;2.38,1.56-3.63;1.82,1.43-2.33)。考虑到特定亚组(即,白种人患者、高质量研究和报告调整关联估计的研究),主要终点的结果没有改变。维生素 D 水平较低的患者因 SARS-CoV-2 感染而出现需要入住重症监护病房(ICU)或死亡的急性呼吸窘迫综合征(ARDS)的风险增加,并且更易感染 SARS-CoV-2 并相关住院治疗。